Issue

Vol. 65 No. 4: Issue 4

The undersigned hereby assign all rights, included but not limited to copyright, for this manuscript to CMB Association upon its submission for consideration to publication on Cellular and Molecular Biology. The rights assigned include, but are not limited to, the sole and exclusive rights to license, sell, subsequently assign, derive, distribute, display and reproduce this manuscript, in whole or in part, in any format, electronic or otherwise, including those in existence at the time this agreement was signed. The authors hereby warrant that they have not granted or assigned, and shall not grant or assign, the aforementioned rights to any other person, firm, organization, or other entity. All rights are automatically restored to authors if this manuscript is not accepted for publication.

Effect of combination of all-trans retinoic acid and arsenic trioxide on apoptosis of acute promyelocytic leukemia cells

https://doi.org/10.14715/cmb/2019.65.4.16
Jiane Hu
Department of Clinical Laboratory, Chongqing Three Gorges Central Hospital, Chongqing City, China
Qiuyan Sun
Department of Pharmacy, Chongqing Three Gorges Central Hospital, Chongqing City, China
Wei Fang
Department of Pharmacy, Chongqing Three Gorges Central Hospital, Chongqing City, China
Qinglin Wang
Department of Clinical Laboratory, Chongqing Three Gorges Central Hospital, Chongqing City, China

Corresponding Author(s) : Qiuyan Sun

b33pvp@163.com

Cellular and Molecular Biology, Vol. 65 No. 4: Issue 4

Abstract

To study the effect of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) combination treatment on apoptosis of acute promyelocytic leukemia cells (NB4), inflammation and prognosis. The effect of ATRA - ATO combination on the proliferation of NB4 was determined using MTT assay. Apoptosis of NB4 cells was assessed with TUNEL assay. The effect of ATRA-As2O3 combination on the expressions of IL-6 and TNF-α in NB4 cells was determined using ELISA kits, while its effect on the quality of life of 25 acute promyelocytic leukemia patients admitted to our hospital was scored, as an index of prognosis. The combination treatment with ATRA and ATO significantly inhibited the proliferation of NB4 cells and promoted their apoptosis, relative to the model group. In addition, the combination treatment reduced serum IL-6 and TNF-α levels in patients with acute promyelocytic leukemia, and improve their quality of life and survival. Combination treatment with ATRA and ATO significantly inhibits the proliferation of NB4 cells and promotes their apoptosis, and reduces inflammatory responses in patients with acute promyelocytic leukemia, while improving their quality of life and prognosis.

Keywords

Acute promyelocytic leukemia All-trans retinoic acid Arsenic trioxide NB4 cells Inflammation.
Hu, J., Sun, Q., Fang, W., & Wang, Q. (2019). Effect of combination of all-trans retinoic acid and arsenic trioxide on apoptosis of acute promyelocytic leukemia cells. Cellular and Molecular Biology, 65(4), 97–100. https://doi.org/10.14715/cmb/2019.65.4.16
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX
References
  1. Testa U, Lo-Coco F. Prognostic factors in acute promyelocytic leukemia: strategies to define high-risk patients. Ann Hematol 2016; 95: 673-680.
  2. Buckley SA, Kirtane K, Walter RB, Lee SJ, Lyman GH. Patient-reported outcomes in acute myeloid leukemia: Where are we now. Blood Rev 2018; 32: 81-87.
  3. Pashaiefar H, Yaghmaie M, Tavakkolybazzaz J, Ghaffari SH, Alimoghaddam K, Pantea I, et al. The Association between PARP1 and LIG3 Expression Levels and Chromosomal Translocations in Acute Myeloid Leukemia Patients. Cell J 2018; 20: 204-210.
  4. Watts JM, Tallman MS. Acute promyelocytic leukemia: what is the new standard of care? Blood Rev 2014; 28: 205-212.
  5. Nguyen R, Houston J, Chan WK, Finkelstein D, Dyer MA. The role of interleukin-2, all-trans retinoic acid, and natural killer cells: surveillance mechanisms in anti-GD2 antibody therapy in neuroblastoma. Cancer Immunol Immunother 2018; 67: 615-626.
  6. Derek MC, Christina B, Harry I. Retinoic acid and arsenic trioxide in the treatment of acute promyelocytic leukemia: current perspectives. Onco Targets Ther 2017; 10: 1585-1601.
  7. Iland HJ, Wei A, Seymour JF. Have all-trans retinoic acid and arsenic trioxide replaced all-trans retinoic acid and anthracyclines in APL as standard of care. Best Pract Res Clin Haematol 2014; 27: 39-52.
  8. Das M. Arsenic trioxide consolidation in APL. Lancet Oncol 2017; 18: 517.
  9. Abaza Y, Kantarjian H, Garcia-Manero G, Estey E, Borthakur G, Jabbour E, et al. Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. Blood 2017; 129: 1275-1283.
  10. Zhu B, Wang J, Zhou F, Liu Y, Lai Y, Wang J, et al. Zinc Depletion by TPEN Induces Apoptosis in Human Acute Promyelocytic NB4 Cells. Cell Physiol Biochem 2017; 42: 1822-1836.
  11. Dunoyer-Geindre S, Rivier-Cordey AS, Tsopra O, Lecompte T, Kruithof EKO. Effect of ATRA and ATO on the expression of tissue factor in NB4 acute promyelocytic leukemia cells and regulatory function of the inflammatory cytokines TNF and IL-1β. Ann Hematol 2017; 96: 905-917.
  12. Sultan S, Irfan SM, Ashar S. Acute Promyelocytic Leukemia: a Single Center Study from Southern Pakistan. Asian Pac J Cancer Prev 2015; 16: 7893-7895.
  13. Giri S, Pathak R, Aryal MR, Karmacharya P, Bhatt VR. Second primary malignancy in acute promyelocytic leukemia: a Surveillance, Epidemiology and End Results database study. Future Oncol 2017; 13: 1455-1457.
  14. Wafa A, Moassass F, Liehr T, Al-Ablog A, Al-Achkar W. Acute promyelocytic leukemia with the translocation t(15;17) (q22; q21) associated with t(1;2) (q42~43; q11.2~12): a case report. J Med Case Rep 2016; 10: 203.
  15. Tomita A, Kiyoi H, Naoe T. Mechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As2O 3) in acute promyelocytic leukemia. Int J Hematol 2013; 97: 717-25.
  16. Cao H, Xie J, Guo L, Han K, Pei Y, Li X, et al. All-trans retinoic acid induces autophagic degradation of ubiquitin-like modifier activating enzyme 3 in acute promyelocytic leukemia cells. Leuk Lymphoma 2018; 59: 1222-1230.
  17. Zhu HH, Guo ZP, Jia JS, Jiang Q, Jiang H, Huang XJ. The impact of oral arsenic and all-trans-retinoic acid on coagulopathy in acute promyelocytic leukemia. Leuk Res 2018; 65: 14-19.
  18. Liu X, Chen J, Yu S, Yan L, Guo H, Dai J, et al. All-trans retinoic acid and arsenic trioxide fail to derepress the monocytic differentiation driver Irf8 in acute promyelocytic leukemia cells. Cell Death Dis 2017; 8: 2782.
  19. Abaza Y, Kantarjian H, Garcia-Manero G, Estey E, Borthakur G, Jabbour E, et al. Long-term outcome of acute promyelocytic leukemia treated with all-r, transr, -retinoic acid, arsenic trioxide, and gemtuzumab. Blood 2017; 129: 1275-1283.
  20. Guo Q, Jiang Q, Liu W, Bai Y. All-trans retinoic acid inhibits HOXA7 expression in leukemia cell NB4. Cell Mol Biol (Noisy-le-grand) 2016; 62: 63-66.
Read More
Author biographies is not available.
Crossref
Scopus
Google Scholar
Europe PMC
Download this PDF file
PDF
Statistic
Read Counter : 902 Download : 453